tradingkey.logo

Elutia Inc

ELUT
查看詳細走勢圖
0.987USD
+0.045+4.73%
收盤 02/06, 16:00美東報價延遲15分鐘
42.00M總市值
虧損本益比TTM

Elutia Inc

0.987
+0.045+4.73%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+4.73%

5天

-5.99%

1月

+48.32%

6月

-50.15%

今年開始到現在

+42.50%

1年

-63.17%

查看詳細走勢圖

TradingKey Elutia Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Elutia Inc當前公司基本面數據相對穩定,最新ESG揭露屬於行業領先水平。增長潛力較大。當前估值合理,在藥品行業排名82/159位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為3.50。中期看,股價處於上升通道。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Elutia Inc評分

相關信息

行業排名
82 / 159
全市場排名
211 / 4521
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Elutia Inc亮點

亮點風險
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
業績增長期
公司處於發展階段,最新年度總收入24.38M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入24.38M美元
估值合理
公司最新PE估值-1.58,處於3年歷史合理位
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉61.99K股

分析師目標

基於 2 分析師
買入
評級
3.500
目標均價
+252.75%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Elutia Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Elutia Inc簡介

Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
公司代碼ELUT
公司Elutia Inc
CEOMills (C. Randal)
網址https://elutia.com/
KeyAI